Review



mab recognizing cd8a  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Bio X Cell mab recognizing cd8a
    Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of <t>Cd8a,</t> Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)
    Mab Recognizing Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+recognizing+cd8a/Anti-Human+CD8+Cd8a+Monoclonal+Antibody+mFluor540+Conjugated%2C+Flow+Validated/pm37814340-61-4-13
    Average 94 stars, based on 18 article reviews
    mab recognizing cd8a - by Bioz Stars, 2026-11
    94/100 stars

    Images

    1) Product Images from "Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity."

    Article Title: Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity.

    Journal: Journal of experimental & clinical cancer research : CR

    doi: 10.1186/s13046-023-02831-w

    Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)
    Figure Legend Snippet: Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)

    Techniques Used: Immunostaining, Flow Cytometry

    Related Articles

    Injection:

    Article Title: Epstein-Barr virus infection induces tissue-resident memory T cells in mucosal lymphoid tissues
    Article Snippet: .. CD8 + T cells were depleted weekly, via i.p. injection beginning at week 3 after infection, with the monoclonal antibody against human CD8 (clone OKT-8; BioXCell). ..

    Article Title: Immunotherapy with conventional type-1 dendritic cells induces immune memory and limits tumor relapse
    Article Snippet: .. For antibody-depletion of CD8 + and CD4 + T cells, mice were intraperitoneally injected with 125 μg anti-CD8b (clone 53-5.8, BioXCell) or anti-CD4 (clone GK1.5, Biolegend) antibodies 3- and 1-day prior tumor re-challenge. .. Control mice were intraperitoneally injected with 125 μg IgG from rat serum (Sigma) on the same days.

    Article Title: Tumour-brain crosstalk restrains cancer immunity via a sensory-sympathetic axis.
    Article Snippet: .. For antibody-mediated T cell depletion, anti-CD4 (GK1.5, BioXCell), anti-CD8 (2.43, BioXCell), or their respective isotype controls were intraperitoneally injected twice weekly at a dose of 200 μg per mouse. ..

    Article Title: Lung adenocarcinoma–derived IFN- γ promotes growth by modulating CD8 + T cell production of CCR5 chemokines
    Article Snippet: .. Mice undergoing antibody depletions received 200 μg of anti-CD8 (clone YTS169.4, BioXCell), 250 μg of anti-IFN-γ (clone H22, BioXCell), and/or 250 μg of anti-TNF-α (clone XT3.11 BioXCell) on days -2 and -1 prior to tumor injection on day 0, and then were continually depleted twice a week for the remainder of the experiment. .. The 129S/Sv-Krastm3Tyj/J mice received 200 μg of anti-CD8 (clone YTS169.4, BioXCell) twice a week from ages 8 to 12 weeks.

    Article Title: Tumour–brain crosstalk restrains cancer immunity via a sensory–sympathetic axis
    Article Snippet: Sulfatrim ( Pharmaceutical Associates , Inc ) water was given for 2 weeks and changed twice weekly. .. For antibody-mediated T cell depletion, anti-CD4 (GK1.5, BioXCell), anti-CD8 (2.43, BioXCell), or their respective isotype controls were intraperitoneally injected twice weekly at a dose of 200 μg per mouse. ..

    Infection:

    Article Title: Epstein-Barr virus infection induces tissue-resident memory T cells in mucosal lymphoid tissues
    Article Snippet: .. CD8 + T cells were depleted weekly, via i.p. injection beginning at week 3 after infection, with the monoclonal antibody against human CD8 (clone OKT-8; BioXCell). ..

    other:

    Article Title: Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity.
    Article Snippet: Article Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity

    Control:

    Article Title: Directed protein engineering identifies a human TIM-4 blocking antibody that enhances anti-tumor response to checkpoint inhibition in murine colon carcinoma
    Article Snippet: Treatments were initiated on day 7 as follows: SKWX301 antibody (low = 25 μg; high = 250 μg) alone or in combination with anti-PD1 antibody (200 μg) (Cd279, Invivomab anti-mouse Pd-1 Clone: Rmp1-14). .. Anti-TIM-4 antibody, clone RMT4-53 (103253-090, Bio X Cell), was used as a reference control, as well as an anti-isotype human monoclonal antibody control (103479-666, Bio X Cell). ..

    Mouse Assay:

    Article Title: Lung adenocarcinoma–derived IFN- γ promotes growth by modulating CD8 + T cell production of CCR5 chemokines
    Article Snippet: .. Mice undergoing antibody depletions received 200 μg of anti-CD8 (clone YTS169.4, BioXCell), 250 μg of anti-IFN-γ (clone H22, BioXCell), and/or 250 μg of anti-TNF-α (clone XT3.11 BioXCell) on days -2 and -1 prior to tumor injection on day 0, and then were continually depleted twice a week for the remainder of the experiment. .. The 129S/Sv-Krastm3Tyj/J mice received 200 μg of anti-CD8 (clone YTS169.4, BioXCell) twice a week from ages 8 to 12 weeks.



    Similar Products

    94
    Bio X Cell mab recognizing cd8a
    Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of <t>Cd8a,</t> Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)
    Mab Recognizing Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+recognizing+cd8a/Anti-Human+CD8+Cd8a+Monoclonal+Antibody+mFluor540+Conjugated%2C+Flow+Validated/pm37814340-61-4-13
    Average 94 stars, based on 1 article reviews
    mab recognizing cd8a - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    90
    Bio X Cell be0061, fully neutralizing mab recognizing cd8a
    Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of <t>Cd8a,</t> Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)
    Be0061, Fully Neutralizing Mab Recognizing Cd8a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+recognizing+cd8a/anti+cd8/pmc10561497-52-0-13
    Average 90 stars, based on 1 article reviews
    be0061, fully neutralizing mab recognizing cd8a - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher a different clone of mab recognizing cd8a (ct-cd8a; igg2a)
    Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of <t>Cd8a,</t> Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)
    A Different Clone Of Mab Recognizing Cd8a (Ct Cd8a; Igg2a), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mab+recognizing+cd8a/10__1182_slash_blood__v96__5__1865-53-31-39
    Average 90 stars, based on 1 article reviews
    a different clone of mab recognizing cd8a (ct-cd8a; igg2a) - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)

    Journal: Journal of experimental & clinical cancer research : CR

    Article Title: Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity.

    doi: 10.1186/s13046-023-02831-w

    Figure Lengend Snippet: Fig. 6 Suppression of CTLs by CD11b+ MDSCs is responsible for the acceleration of tumor progression by Regnase-1 downregulation. A-D Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1 KO murine pancreatic cancer cells. Representative macro images of pancreatic tumors (A). Relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (B) (N = 6 per group). Representative images of HE (C, left panel) and CD8a immunostaining (C, right panel) and the number of CD8-positive cells (C, right) (N = 6 per group). Dot plots of CD3+CD8+ cells evaluated by flow cytometry (D, left) and the proportion of CD8 + cells among CD45+ cells (D, right) (N = 3 per group). E–H Evaluation of phenotypes of orthotopic syngeneic tumors of WT or Regnase-1-KO murine pancreatic cancer cells with or without depletion of CD8+ cells upon anti-CD8a antibody or IgG treatment. Experimental schematic (E). Dot plots of CD3+ and CD8.+ cells in WT or Regnase-1-KO syngeneic tumors upon anti-CD8a antibody or IgG treatment evaluated by flow cytometry (F). Tumor weights (G) (N = 6 per group). The relative mRNA levels of Cd8a, Ifng, Fasl, and Gzmb (H) (N = 6 per group). Student’s t test was used to evaluate differences between 2 groups. One-way ANOVA with Tukey’s post hoc test was used to compare differences among 4 groups. *P < 0.05, scale bars: 100 μm (insets)

    Article Snippet: BE0061, a fully neutralizing mAb recognizing CD8a, and control IgG were obtained from Bioxcell.

    Techniques: Immunostaining, Flow Cytometry